Dr. Mato on Utilizing CAR T Cells in CLL


Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia (CLL).

As of today, CAR T cell-therapy is not approved by the FDA and is only available in the context of a clinical trial, says Mato.

However, the novel concept of modulating the immune system to kill cancer cells does have relevance in CLL, despite the number of targeted therapies that have emerged, such as ibrutinib (Imbruvica) and venetoclax (Venclexta).

Small studies have reported promising data regarding CAR T cells alone or in combination with drugs like ibrutinib, but it remains unknown what setting CAR T cell-therapy should be used in.

Mato believes that CAR T-cell therapy could potentially be used where transplant once was. However, it is too early to say whether CAR T cells will impact the paradigm.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.